Biotech CSL has reported an 11 per cent leap in first half net profit to $US1.25 billion and upgraded its full year profit guidance.
The blood products manufacturer said it now expected full year profit to be about 10 per cent to 13 per cent on FY19, in the range of $US2.1 billion to $US2.17 billion.
Profit for the six months to December 31 rose 8.0 per cent on a constant currency basis while total operating revenue grew 11 per cent to $US4.9 billion.
Growth in CSL’s key immunoglobulin products, haemophilia therapies and seqirus influenza vaccines, as well as progress on a China distribution model were the key contributors to its profit increase.
Shareholders will receive a dividend of 95 US cents per share, unfranked.
That’s an increase on the 85 US cents paid 12 months ago.